



БУХОРО ДАВЛАТ ТИББИЁТ
ИНСТИТУТИ



ISSN 3030-3877

DOI Journal 10.26739/3030-3877

ANNALS OF CLINICAL DISCIPLINE

2 ЖИЛД, 4/1 СОН

АННАЛЫ КЛИНИЧЕСКИХ ДИСЦИПЛИН

ТОМ 2, НОМЕР 4/1

КЛИНИК ФАНЛАР ЙИЛНОМАСИ

VOLUME 2, ISSUE 4/1



ТОШКЕНТ-2025

BOSH MUHARRIR: | ГЛАВНЫЙ РЕДАКТОР: | CHIEF EDITOR:

Sh. J. Teshayev

“Klinik fanlar yilnomasi” jurnali bosh muharriri, Buxoro davlat tibbiyot instituti rektori, t.f.d., professor

BOSH MUHARRIR O'RINBOSARI: | ЗАМЕСТИТЕЛЬ ГЛАВНОГО РЕДАКТОРА: | DEPUTY CHIEF EDITOR:

D. A. Xasanova

“Klinik fanlar yilnomasi” jurnali bosh muharrir o'rinbosari, Buxoro davlat tibbiyot instituti anatomiya va klinik anatomiya kafedrasida professori, DSc

РЕДАКЦИОННАЯ КОЛЛЕГИЯ:

- **U.K. Abdullayeva** - “Klinik fanlar yilnomasi” jurnali mas'ul kotibi, Buxoro davlat tibbiyot instituti fakultet va gospital terapiya, nefrologiya va gemodializ kafedrasida dotsenti, DSc
- **M.J. Sanoyeva** - Buxoro davlat tibbiyot instituti nevrologiya kafedrasida dotsenti, DSc
- **A.G. Gadayev** - Toshkent tibbiyot akademiyasi 3-son ichki kasalliklar kafedrasida professori, t.f.d.
- **A.R. Obloqulov** - Buxoro davlat tibbiyot instituti, yuqumli kasalliklar va bolalar yuqumli kasalliklari kafedrasida mudiri, t.f.d., professor
- **D.A. Nabiyeva** - Toshkent tibbiyot akademiyasi, 1-son fakultet va gospital terapiya, kasb kasalliklari kafedrasida mudiri, t.f.d., professor
- **Sh.T. O'roqov** - Buxoro davlat tibbiyot instituti xirurgik kasalliklar kafedrasida mudiri, DSc, dotsent
- **M.M. Karimov** - Respublika ixtisoslashtirilgan terapiya va reabilitatsiya ilmiy-amaliy tibbiyot markazi “Gastroenterologiya” ilmiy laboratoriyasi boshlig'i, t.f.d., professor
- **N.U. Narzullayev** - Buxoro davlat tibbiyot instituti otorinolaringologiya kafedrasida professori, DSc
- **G.N. Sobirova** - Toshkent tibbiyot akademiyasi reabilitatsiya va jismoniy tarbiya kafedrasida professori, t.f.d.
- **F.S. Raupov** - Buxoro davlat tibbiyot instituti bolalar xirurgik kasalliklari kafedrasida mudiri, DSc, dotsent
- **Sh.B. Axrorova** - Buxoro davlat tibbiyot instituti, nevrologiya kafedrasida dotsenti, DSc
- **V.R. Akramov** - Buxoro davlat tibbiyot instituti travmatologiya va neyroxirurgiya kafedrasida mudiri, DSc, dotsent
- **I.K. Sadulloeva** - Buxoro davlat tibbiyot instituti bolalar kasalliklari propedevtikasi va bolalar nevrologiyasi kafedrasida mudiri, DSc, dotsent
- **M.K. Temirova** - Toshkent davlat tibbiyot universiteti, Nevrologiya va bolalar nevrologiyasi, tibbiy genetika kafedrasida assistenti PhD

РЕДАКЦИОННЫЙ СОВЕТ:

- **G.J. Jarilkasinova** - Buxoro davlat tibbiyot instituti oilaviy shifokorlarni qayta tayyorlash kafedrasida professori, DSc
- **U.S. Mamedov** - Buxoro davlat tibbiyot instituti onkologiya kafedrasida mudiri, DSc, dotsent
- **A.A. Saidov** - Buxoro davlat tibbiyot instituti ortopedik stomatologiya va ortodontiya kafedrasida professori DSc
- **N.N. Karimova** - Buxoro davlat tibbiyot instituti 3-son akusherlik va ginekologiya kafedrasida mudiri, DSc, dotsent
- **U.K. Qayumov** - tibbiyot xodimlarini kasbiy malakasini oshirish markazi ichki kasalliklar kafedrasida mudiri, t.f.d., professor
- **M.E. Raximova** - Toshkent tibbiyot akademiyasi, 3-son ichki kasalliklar kafedrasida dotsenti, t.f.d.
- **R.I. To'raqulov** - Toshkent tibbiyot akademiyasi, 3-son ichki kasalliklar kafedrasida professori, t.f.d.
- **Ch.S. Pavlov** - I.M. Sechenov nomidagi birinchi Moskva davlat tibbiyot universiteti terapiya kafedrasida mudiri, t.f.d., professor
- **L.B. Novikova** - Rossiya Federatsiyasi Sog'liqni saqlash vazirligining “Janubiy Ural davlat tibbiyot universiteti” federal davlat byudjet oliy ta'lim muassasasi dermatovenerologiya kafedrasida professori, t.f.d.
- **O.I. Letyayeva** - Rossiya Federatsiyasi Sog'liqni saqlash vazirligining “Janubiy Ural davlat tibbiyot universiteti” federal davlat byudjet oliy ta'lim muassasasi dermatovenerologiya kafedrasida professori, t.f.d.
- **I.V. Reverchuk** - I.Kant nomidagi Boltiq federal universiteti psixonevrologiya va psixosomatika kafedrasida mudiri, t.f.d., professor
- **Edip Gonullu** - Izmir Bakirchay universiteti anesteziya va reanimatsiya kafedrasida dotsenti, t.f.d.
- **Eva Lietto** - Italiya Campania universiteti “Luigi Vanvitelli”ning tarjima tibbiyot fanlari kafedrasida mudiri, t.f.d., professor
- **G.S. Xodjiyeva** - Abu Ali ibn Sino nomidagi Buxoro davlat tibbiyot universitetining Ichki kasalliklar propedevtikasi kafedrasida dotsenti

Журнал включен в перечень ВАК национальных научных изданий, рекомендуемых для публикации основных научных результатов диссертаций по медицинским наукам постановлением № 369/6 от 5 апреля 2025 г.

© Page Maker | Верстка | Саҳифаловчи: Хуршид Мирзахмедов

О журнале

Журнал зарегистрирован в Агентство информации и массовых коммуникаций при Администрации Президента Республики Узбекистан № С-239963 от 14 марта 2024 года

Адрес редакции: Республика Узбекистан, 200114, г. Бухара, ул. Гиждуван, 23
Телефон: +998(65)2230050
Сайт: <https://tadqiqot.uz/index.php/spjacad>
e-mail: abumkur14@gmail.com

1. Abdullayeva U.K., Rakhimova M.B. Ulcerative colitis: risk factors.....	6
2. Ibrohimov S.I. Bolalik yoshida kuzatiladigan ekssudativ o‘rta otit rivojlanishining asosiy sabablari.....	10
3. Jahonqulova S.O., Po‘latova Sh.H. Eksperimental bosh miya travmasida morfologik o‘zgarishlar va ularning intensiv terapiya samaradorligiga ta’siri.....	20
4. Kayumova G.M. Clinical and morphological features of tubal pregnancy.....	30
5. Madjidova Y.N., Isakova G.S., Sharipov F.R. Evaluation of the effectiveness of a mechanical rehabilitation glove in school-aged patients with cerebral palsy in the Andijan region.....	36
6. Maxamatov U.Sh. Maktab muassasalarining ta’lim va tarbiya sharoitlarini gigiyenik jihatdan asoslash va takomillashtirish (Farg‘ona viloyati misolida).....	43
7. Nabiraeva B.A. Temporomadibular bo‘g‘im disfunktsiyasida qisman adentiali bemorlarda teri orqali neyrostimulyatsiyani qo‘llash.....	49
8. Nazarov B.B., Karimova N.N. Description of the results of a comparative study of immunoglobulin content in the serum of women with pre-cervical tumor.....	54
9. Rasulov A.S., Rasulova N.A. The use of an immunostimulator to assess the quality of immunological status in children.....	60
10. Rasulova N.A., Rasulov A.S. Strategies for providing vitamin D based on blood biochemical indicators in rachitis.....	65
11. Абдуллаева Ф.О. Туберкулёз лёгких и сопутствующие патологии – проблемы коморбидности, патогенеза и ведения пациентов.....	69
12. Абдулхакимов Ш.А. Технические принципы и особенности выполнения КТ-исследований у больных с врождёнными аномалиями сердца	73
13. Абдулхаков И.У., Абдулхаков М.И. Современные представления о нейрогенезе у человека.....	85
14. Абдурахмонов И.И., Умаров Б.Я. Иммунологические детерминанты риска развития послеоперационного энтероколита при болезни Гиршпрунга у детей.....	90
15. Абрайкулов И.Р., Муротов Н.Ф. Бачадон бўйни саратони ташхисланган аёллар қон зардобда интерферон гамманинг микдорий параметрлари қиёсий тавсифи.....	96
16. Акилов Х.А., Примов Ф.Ш., Напасов С.С., Сапаев Д.Ш. Клинико-эпидемиологические особенности посттравматического панкреатита у детей.....	104

17. Акрамов О.З., Аблязов О.В, Кадыров Ш.У.	
Оптимизация нейровизуализации и хирургических доступов при опухолях функционально значимых зон головного мозга у детей.....	113
18. Алиджанова Д.А.	
Нейроспецифические белки как маркеры когнитивного дефицита у детей и подростков, страдающих СД 1-типа.....	119
19. Алиханова Н.М., Исамухамедова И.С., Аббосхужаева Л.С.	
Вариабельность глюкозы у больных сахарным диабетом 2 типа в зависимости от гликемической нагрузки и гликемического индекса ингредиентов продуктов питания.....	128
20. Аскарров Ш.Ш., Салахитдинов Ш.Н.	
Интервенционные стратегии реперфузии при массивном тромбозе коронарных артерий: клиничко-ангиографическое сравнение трёх методов.....	135
21. Ахмеджанова С.Ф.	
Функциональная гипоталамическая аменорея: современные представления о патогенезе, диагностике и терапии.....	142
22. Байрамов С.Д., Султанов С.Н.	
Роль недифференцированной дисплазии соединительной ткани в развитии истмико-цервикальной недостаточности и преждевременных родов.....	146
23. Бахронов Б.Б.	
Морфологические и морфометрические критерии синергетического действия <i>Silybum marianum</i> и <i>Carthamus tinctorius</i> при хроническом поражении пищевода угарным газом.....	151
24. Бердиева Х.У.	
Особенности интерпритации показателей интерлейкинов при когнитивных расстройствах у детей с задержкой речевого развития.....	159
25. Ганжиев Ф.Х., Хамдамов Б.З.	
Травматические повреждения печени: эпидемиология, клиничко-патологические последствия (обзорный взгляд).....	165
26. Джурабекова С.Т., Бойбекова А.Ф.	
Оптимизация послеабортной реабилитации после прерывания беременности в ранних сроках с применением кок с фолатами по схеме "Quick start": гормональный и репродуктивный эффект.....	171
27. Досмухамедова Л.В., Эргашев Б.Б.	
Лечение детей с венозными мальформациями нижних конечностей.....	184
28. Ибрагимов А.У., Хомидов Ф.К.	
Повышение эффективности профилактики хронических респираторных заболеваний среди взрослого населения на основе комплексных и персонализированных мероприятий.....	190
29. Ахмедова Дилдорахон Садиллахужаевна	
Клиничко-неврологические признаки вторичных энцефалитов у детей.....	197
30. Khushvakova Nilufar Zhurakulovna, Xamidova Farida Mo'minovna, Bo'riyeva Dilnoz Vaxriddinovna	
Chronic hypertrophic laryngitis leukokeratosis and leukoplakia.....	201




UDC: 618.1 DOI: 10.24412/1609-2163-2022-1-29-33

Nazarov B.B.<https://orcid.org/0009-0002-9889-4358>**Karimova N.N.**<https://orcid.org/0009-0007-9349-8029>

Bukhara State Medical Institute, Bukhara, Uzbekistan

DESCRIPTION OF THE RESULTS OF A COMPARATIVE STUDY OF IMMUNOGLOBULIN CONTENT IN THE SERUM OF WOMEN WITH PRE-CERVICAL TUMOR

 <http://dx.doi.org/10.5281/zenodo.18207922>

ABSTRACT

The study examined changes in serum immunoglobulins in women with precancerous cervical lesions. Cervical cancer in women is characterized by a severe course, poor treatment efficacy, and often fatal outcome. Precancerous cervical diseases have been proven to be among the main risk factors for this medical and socio-economic problem[1]. Therefore, it is advisable to have biological markers and clinical laboratory criteria that clearly identify the disease. Taking into account the above, this study aimed to conduct a comparative investigation of the serum concentrations of humoral immune factors in women with precancerous cervical conditions.

Keywords: immunoglobulin, humoral immunity, biological marker, humoral factor, plasma cells.

Назаров Б.Б., Каримова Н.Н.

Бухарский государственный медицинский институт, Бухара, Узбекистан

СРАВНИТЕЛЬНЫЕ РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЙ СОДЕРЖАНИЯ ИММУНОГЛОБУЛИНОВ В СЫВОРОТКЕ КРОВИ ЖЕНЩИН С ОПУХОЛЯМИ ПРЕЦЕРВИКАЛЬНОЙ ОБЛАСТИ

АННОТАЦИЯ

В исследовании изучались изменения сывороточных иммуноглобулинов у женщин с предраковыми заболеваниями шейки матки. Рак шейки матки у женщин отличается тяжелым течением, низкой эффективностью лечения и часто заканчивается летальным исходом. Доказано, что предраковые заболевания шейки матки являются одними из основных факторов риска этой медицинской и социально-экономической проблемы. Таким образом, целесообразно наличие биологических маркеров и клинико-лабораторных критериев, позволяющих однозначно идентифицировать данное заболевание. Учитывая вышесказанное, целью исследования было проведение сравнительного изучения концентраций гуморальных факторов иммунитета в сыворотке крови женщин с предраковыми состояниями шейки матки.

Ключевые слова: иммуноглобулин, гуморальный иммунитет, биологический маркер, гуморальный фактор, плазматические клетки.

Nazarov B.B., Karimova N.N.

Buxoro davlat tibbiyot instituti, Buxoro, O'zbekiston

PRESERVIKAL HUDUDNING O'SMALARI BO'LGAN AYOLLARNING QON ZARDOBIDAGI IMMUNOGLOBULIN TARKIBINI O'RGANISHNING QIYOSIY NATIJALARI.

REZYUME

Tadqiqotda bachadon bo'yni saratonidan oldingi lezyonlari bo'lgan ayollarda sarum immunoglobulinlaridagi o'zgarishlar o'rganildi. Ayollarda bachadon bo'yni saratoni og'ir kurs, past davolash samaradorligi bilan tavsiflanadi va ko'pincha o'limga olib keladi. Bachadon bo'yni saratonidan oldingi shikastlanishlar ushbu tibbiy va ijtimoiy-iqtisodiy muammoning asosiy xavf omillaridan biri ekanligi isbotlangan. Shuning uchun bu kasallikni aniq aniqlash uchun biologik belgilar va klinik laboratoriya mezonlarining mavjudligi juda muhimdir. Yuqoridagilarni hisobga olgan holda, tadqiqotning maqsadi bachadon bo'yni prekanserov kasalliklari bo'lgan ayollarning qon zardobidagi gumoral immunitet omillarining konsentratsiyasini qiyosiy o'rganish edi.

Kalit so'zlar: immunoglobulin, gumoral immunitet, biologik marker, gumoral omil, plazma hujayralari.

Introduction: Cervical cancer in women is distinguished by a severe course, low treatment success, and frequent fatal outcomes. It has been shown that precancerous conditions of the cervix are among the key risk factors for this medical and socio-economic issue[3,10]. Thus, early detection and uncomplicated treatment of precancerous cervical conditions are of great importance. A variety of diagnostic methods are recommended and must be under continuous monitoring. However, one of the biggest challenges is initial detection, because women who consider themselves healthy and have no pain or discomfort symptoms are unlikely to seek medical help. This situation is also influenced by cultural and social factors; the problem of timely medical consultation remains a leading issue[2,4].

In many cases, precancerous cervical lesions are detected incidentally during a primary medical visit for another issue. Therefore, it is reasonable to develop and utilize biological markers and clinical laboratory criteria that would definitively diagnose this condition[3,8].

The immune system is one of the most sensitive systems in the body with respect to early pathological changes. Its immunocompetent cells and humoral immune factors respond to ongoing asymptomatic, subclinical conditions with quantitative and qualitative changes. It has been shown that shifts in their quantities and balance can indicate the presence of pre-disease states in the organism[10,4].

Taking the above into account, the objective of this research was set to comparatively study the serum concentrations of humoral immune factors in women with precancerous cervical lesions.

Materials and Methods. A total of 252 women of various ages were enrolled in the clinical study. Immunological investigations were performed on 76 of these patients; 15 healthy women with no detected cervical pre-cancerous or cancerous conditions were included as the control group.

All participants were divided into four representative study groups:

- **Group 1 (n=23):** Women diagnosed with precancerous cervical lesions (dysplastic process) who had not received any treatment.
- **Group 2 (n=26):** Women with precancerous cervical lesions (dysplastic process) who received conservative treatment.
- **Group 3 (n=26):** Women with early-stage cervical cancer (stage 0–I) who underwent radiation and chemotherapy.
- **Group 4 (Control, n=15):** Healthy women in whom no precancerous or cancerous cervical lesions were observed during the study period.

The serum concentration of IgA was determined using ELISA test kits from Vector Best (Novosibirsk, Russia). IgM, IgG, and IgE were measured using ELISA test kits from Xema (Moscow, Russia). Enzyme-linked immunosorbent assays were carried out on a MR-96A analyzer (Mindray Co. Ltd, China) manufactured in 2022.

The obtained data were statistically processed using standard methods of variance statistics with the Excel software. The arithmetic mean (M) and standard error of mean (m) were calculated. Differences were evaluated for statistical significance using the Fisher–Student criterion (P).

Results. Serum levels of all measured immunoglobulins in the patient groups were significantly higher than in healthy women ($P < 0.05$ to $P < 0.001$), although all values remained within the upper reference ranges ($P > 0.05$). This suggests that, while these pathologies induce significant changes in immunoglobulin concentrations, the overall immune response activation remains relatively low. Nevertheless, the findings indicate that these immune proteins can respond to even minimal antigenic stimulation.

Table 1
Serum immunoglobulin parameters in women with precancerous cervical lesions (untreated)

Immunoglobulin	Healthy women, n=15	Group 1 (dysplasia, no treatment), n=23
IgA (g/L) (ref 0.9–5.0)	3.35 ± 0.33	6.05 ± 0.35* ↑
IgM (g/L) (ref 0.7–3.7)	2.41 ± 0.22	4.21 ± 0.34* ↑
IgG (g/L) (ref 9–20)	15.05 ± 0.62	18.76 ± 0.65* ↑
IgE (pg/mL) (ref 160–288)	207.83 ± 6.92	228.74 ± 6.00* ↑

Note: * — significant difference compared to healthy controls; ↑ — direction of change compared to controls.

Specifically, serum IgA in patients averaged 6.05±0.35 g/L, which was 1.81-fold higher than in healthy women (3.35±0.33 g/L, $P < 0.001$). This elevation is consistent with the known function of IgA. IgA is abundantly present in serum and primarily produced on mucous membranes in the form of secretory IgA, constituting the first line of defense against antigens. The secretory component protects IgA from degradation. Considering the impact of human papillomavirus (HPV) on the genital tract, the increased IgA likely reflects an immune response to the virus; alterations in the vaginal microbiota under HPV influence may also support the elevated production of IgA (both in serum and as sIgA on mucosal surfaces).

IgM, another key immunoglobulin, has a large pentameric structure with 10 antigen-binding sites, making it crucial in the primary immune response. Due to its large molecular size, IgM is produced in smaller quantities, normally resulting in the lowest baseline concentration in blood. In this study, however, IgM levels in patients showed a statistically significant increase (1.75-fold compared to healthy controls; see Table 2).

Table 2
Immunoglobulin concentrations in the serum of women with precancerous cervical lesions (treated and untreated)

Immunoglobulin	Control, n=15	Group 1 (no treatment), n=23	Group 2 (treatment), n=26
IgA (g/L) (0.9–5.0)	3.35 ± 0.33	6.05 ± 0.35* ↑	3.13 ± 0.15 ↔
IgM (g/L) (0.7–3.7)	2.41 ± 0.22	4.21 ± 0.34* ↑	2.98 ± 0.10 ↔
IgG (g/L) (9–20)	15.05 ± 0.62	18.76 ± 0.65* ↑	15.15 ± 0.47 ↔
IgE (pg/mL) (160–288)	207.83 ± 6.92	228.74 ± 6.00* ↑	276.10 ± 9.41* ↑ ^

Note: * — significant difference from control; ^ — significant difference from Group 1; ↑/↓ — direction of change; ↔ — no significant difference.

From Table 2, it is clear that the groups differ significantly. All parameters in Group 1 were significantly elevated relative to the control ($P < 0.05$ – $P < 0.001$), whereas in Group 2 (post-treatment) these parameters approached the control values and did not differ significantly from them (except

for IgE). Notably, IgA levels in Groups 2 and control were not significantly different (3.35 ± 0.33 vs. 3.13 ± 0.15 g/L, $P > 0.05$). Compared to Group 1, treated patients (Group 2) showed a significant 1.93-fold decrease in IgA (6.05 ± 0.35 vs. 3.13 ± 0.15 g/L, $P < 0.001$), demonstrating a clear effect of treatment on this immunoglobulin. A similar pattern was observed for IgM: in Group 1 it was significantly higher than normal (1.75-fold, $P < 0.05$), whereas in Group 2 it fell back to near the control level (2.98 ± 0.10 vs. 2.41 ± 0.22 g/L, $P > 0.05$); the relative decrease was 1.41-fold ($P < 0.05$).

IgG changes were analogous: in controls it was 15.05 ± 0.62 g/L, while for patients in Groups 1 and 2 it was 18.76 ± 0.65 g/L and 15.15 ± 0.47 g/L, respectively. The difference between control and Group 2 was not statistically significant ($P > 0.05$), whereas between Group 1 and Group 2 it was significant – Group 2's IgG level was 1.24 times lower than Group 1's ($P < 0.05$). Thus, the three main immunoglobulin classes (IgA, IgM, IgG) showed similar directional changes across groups, whereas IgE behaved differently.

Serum IgE in patient groups continued to rise even after treatment. In the control group it was 207.83 ± 6.92 pg/mL, in Group 1 it rose by a factor of 1.10 (228.74 ± 6.00 pg/mL, $P < 0.05$), and in Group 2 it further increased to 276.10 ± 9.41 pg/mL (a 1.33-fold rise vs. control, $P < 0.05$). Group 1 patients with dysplasia showed uniform increases in all immunoglobulins, while Group 2 patients (after treatment) exhibited pronounced quantitative rebalancing.

Next, the levels of women with dysplasia (Groups 1–2) were compared to those with early-stage cervical cancer (Group 3, stage 0–I). The comparative results are shown in Table 3.

Table 3

Comparative levels of immunoglobulins in the serum of healthy women and women with precancerous cervical lesions (dysplasia) and with early-stage cervical cancer

Immunoglobulin	Control (mean \pm SE) (1 \times)	Group 1, n=23 (dysplasia)	Group 2, n=26 (post-treatment)	Group 3, n=26 (0–I stage cancer)
IgA (g/L) (0.9–5.0)	3.35 ± 0.33 (1 \times)	$6.05 \pm 0.35^* \uparrow$	$3.13 \pm 0.15 \leftrightarrow ^\wedge$	$1.80 \pm 0.17^* \downarrow ^\circ$
IgM (g/L) (0.7–3.7)	2.41 ± 0.22 (1 \times)	$4.21 \pm 0.34^* \uparrow$	$2.98 \pm 0.10 \leftrightarrow ^\wedge$	$1.69 \pm 0.14^* \downarrow ^\circ$
IgG (g/L) (9–20)	15.05 ± 0.62 (1 \times)	$18.76 \pm 0.65^* \uparrow$	$15.15 \pm 0.47 \leftrightarrow ^\wedge$	$8.94 \pm 0.48^* \downarrow ^\circ$
IgE (pg/mL) (160–288)	207.83 ± 6.92 (1 \times)	$228.74 \pm 6.00^* \uparrow$	$276.10 \pm 9.41^* \uparrow ^\wedge$	$219.52 \pm 7.04 \leftrightarrow ^\circ$

Note: * — significant difference from control; \uparrow/\downarrow — direction of change; $^\wedge$ — significant difference from Group 1; $^\circ$ — significant difference from Group 2; \leftrightarrow — no significant difference.

The data in Table 3 show that immunoglobulin levels changed in different ways across the groups. The directions and magnitudes of change varied, reflecting the influence of antigenic stimulation, disease stage, and treatment. Statistically significant differences between groups were observed for most parameters ($P < 0.05$ – $P < 0.001$). These changes are primarily associated with disease progression and treatment impact.

Notably, patients in Group 3 (early-stage cancer) showed completely different immunoglobulin profiles compared to Groups 1 and 2. The main immunoglobulin levels in Group 3 were significantly lower than in Groups 1 and 2 ($P < 0.05$), except for IgE, where differences were only partial, though the overall trend was similar. Importantly, women in Group 3 exhibited significant decreases in all immunoglobulins not only compared to Groups 1 and 2 but also relative to healthy controls ($P < 0.05$).

Discussion. In women with precancerous cervical conditions (dysplasia), serum immunoglobulin levels were significantly elevated compared to healthy controls ($P<0.05$ – $P<0.001$), with the same direction of increase across all classes. However, the intensity of change differed: for example, the increase in IgG was less pronounced than that of IgA and IgM. Specifically, IgA increased 1.81-fold, IgM 1.75-fold, and IgG 1.25-fold in patients relative to controls (all $P<0.05$ – $P<0.001$).

In untreated patients with dysplasia (Group 1), IgA, IgM, IgG, and IgE all rose significantly (same direction, varying degrees). In treated patients (Group 2), these markers significantly decreased ($P<0.05$) to reach levels comparable to healthy women, with no significant differences remaining (except IgE). IgE was the only exception, continuing to rise even after therapy, remaining significantly higher than in both healthy and untreated women.

These quantitative immunoglobulin changes and imbalances are likely linked to inflammation associated with the dysplastic process and immune system activity. After standard treatment, the marked decrease in immunoglobulin levels correlates with therapeutic success; the persistent elevation of IgE may be explained by lack of antihistamine therapy and the increasing allergic component of the inflammatory process.

Thus, significant increases in IgA, IgM, IgG, and IgE (1.10–1.81-fold) in dysplasia can serve as diagnostic and treatment-response indicators, whereas their decline following radiation and chemotherapy (up to 1.43–1.86-fold reductions relative to controls) can serve as prognostic markers of treatment efficacy. We propose using these changes together with clinical symptoms and pre-pathological diagnostics as combined diagnostic and prognostic biomarkers, which is a novel recommendation from our study.

Conclusions

1. In women with precancerous cervical lesions, serum immunoglobulin levels showed a uniform trend of increase, although the degree of change varied. Specifically, IgA was 1.81 times higher than normal, IgM 1.75 times, and IgG 1.25 times in patients ($P<0.05$ – $P<0.001$).

2. In untreated women (dysplasia), IgA, IgM, IgG, and IgE increased significantly, whereas in treated women these indicators significantly decreased to reach control levels, with no significant differences from controls. The exception was IgE, which continued to rise after treatment (remaining significantly higher than in healthy and untreated women).

3. It was shown that the significant increases of IgA, IgM, IgG, and IgE (1.10–1.81-fold) in precancerous cervical conditions can be used as diagnostic and treatment-effect markers, while their decreases during radiation and chemotherapy (up to 1.43–1.86-fold lower than normal) serve as prognostic markers. Using these together with clinical symptoms and pre-cancer diagnostics as combined diagnostic and prognostic biomarkers is recommended for the first time.

List of used literature

1. Gizinger O.A. Immunomodulation in gynecology. Opinions of an immunologist and an obstetrician-gynecologist. Practical questions of colposcopy // *Genital Infections*. – 2022. – No.2. – P.18-23.
2. Abakumova T.V., Myagdieva I.R., Dolgova D.R., Gening S.O., Antoneyeva I.I., Gening T.P. IL-4 and its polymorphism (IL4-589C/T) in cervical neoplasia // *Medical Immunology*. – 2023. – Vol.25, No.5. – P.1129-1134.
3. Belyavskaya V.A., Cherdyntseva N.V., Kzyszkovska Yu.G., Litvyakov N.V. Microbiome, immune system and cancer: three sides of the same medal // *Siberian Oncological Journal*. – 2022. – No.21(6). – P.131-144.
4. Ikhtiyarova G.A., Navruzova N.O., Karimova G.K. Modern diagnostic methods for early detection of cervical diseases // *Doktor Axborotnomasi*. – 2019. – No.4. – P.78-80.
5. Mazitova M.I., Bikineev M.S. Stages of cytological screening for cervical cancer // *R.M.J. Mother and Child*. – 2019. – Vol.2, No.4. – P.322-326.

6. Loginova O.P., Shevchenko N.I., Gasich E.L. Peculiarities of local vaginal immunity in HPV-negative cervical dysplasia // *Medical-Biological Science News*. – 2025. – Vol.25, No.3. – P.230-239.
7. Mamedov U.S., Mirakhmedova S.S. Dynamics of women's immune status during cervical HPV treatment // *Bulletin of Science and Education*. – 2020. – No.24(102), Pt.3. – P.81-84.
8. Semiglazov V.F., Tseluyko A.I., Balduyeva I.A., Nekhaeva T.L., Artemieva A.S., Kудaybergenova A.G. et al. Immunology and immunotherapy in combined treatment of malignant tumors // *Medical Council*. – 2021. – No.4. – P.248-257.
9. Petrov Yu.A., Blesmanovich A.E., Bagnovskaya A.G. From background processes to cervical cancer: causes, diagnosis, and prevention // *Glavvrach of South Russia*. – 2020. – Vol.74, No.4. – P.36-39.
10. Zhen S., Lu J., Liu Y.-H., Chen W., Li X. Synergistic antitumor effect on cervical cancer by rational combination of PD-1 blockade and CRISPR-Cas9-mediated HPV knockout // *Cancer Gene Therapy*. – 2019. – Vol.27. – P.168-178.

ANNALS OF CLINICAL DISCIPLINE

АННАЛЫ КЛИНИЧЕСКИХ ДИСЦИПЛИН КЛИНИК ФАНЛАР ЙИЛНОМАСИ

Научно-практический журнал по всем
направлениям медицины
основан в 2024 году
Бухарским государственным
медицинским институтом
Выходит один раз в 3 месяца
Учредитель Бухарский государственный
медицинский институт